Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Sotorasib + Chemotherapy in 2L KRAS G12C Pancreatic Cancer
NCT05251038Phase 2Withdrawn
- Start
- Sep 2022
- Primary completion
- Jan 2023
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of sotorasib in pancreatic cancer (PC). Primary endpoint: Objective Response Rate at 2 years. Planned start Sep 2022; status: withdrawn.
02
Drugs
sotorasib
03
Conditions
pancreatic cancer (PC)
Beyond the preview
Go deeper on NCT05251038.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05251038.